Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center have announced plans to construct a new, state-of-the-art inpatient hospital exclusively for adult cancer care. This move ends Dana-Farber's almost three-decade-long relationship with Brigham and Women's Hospital and signals a substantial shift in the city's healthcare landscape according to the Boston Globe.
The new hospital will be located on Beth Israel's Longwood Medical Area campus and will be operated under the Dana-Farber license, with Beth Israel Deaconess Medical Center and its affiliated physician group, Harvard Medical Faculty Physicians, providing surgical oncology care and medical subspecialty expertise. According to Dr. Laurie Glimcher, chief executive of Dana-Farber, the collaboration aims to improve patient experience and enhance the quality of care for adult cancer patients.
This new collaboration represents the culmination of a mutually held vision to create an independent cancer center that offers a comprehensive range of oncology services/extensions. Since the mid-90s, Dana-Farber's inpatient oncology care was provided at Brigham and Women's Hospital, following safety concerns in the aftermath of Boston Globe health columnist Betsy Lehman's tragic death due to chemotherapy overdose during treatment at Dana-Farber. The decision to build a dedicated adult cancer hospital comes after careful consideration of whether to re-establish inpatient capabilities internally or partner with another medical institution.
Dr. Kevin Tabb, chief executive of Beth Israel Lahey Health, highlighted the importance of having a dedicated space for adult cancer care, stating that better outcomes can be achieved when dedicating a facility and a team to a specific disease state. With a growing need for inpatient care, driven by an aging population and increasing cancer cases among young adults, the collaboration seeks to increase adultpatient capacity and create flexibility to incorporate innovations and technology in cancer care as reported by Bakersfield.com.
It is important to note that despite the shift in collaboration, both Dana-Farber and Beth Israel Deaconess Medical Center will remain independent, retaining their current executive leadership, boards of trustees, and philanthropic endeavors. Inpatient oncology care at Brigham and Women's Hospital will continue for at least the next five years, while Dana-Farber's pediatric oncology care partnership with Boston Children's Hospital will remain unaffected.
The timeline for the establishment of the new clinical building, integration of hospital programs, and relocation of Joslin Diabetes Center is yet to be detailed, as regulatory approvals from the city, state, and federal authorities are still pending. Additionally, the collaboration emphasizes on improving access, better integrating innovations at the bedside, and offering high-value care to cancer patiients.
